

Supplement Table 1. The visit schedule of DSPN group

Time of Follow-up Items	Post-transplantation						
	Baseline	2 days	1 week	4 weeks	12 weeks	24 weeks	48 weeks
Routine tests	√	√	√	√	√	√	√
NCV	√				√		√
TCSS	√			√	√	√	√
Inflammatory cytokines	√	√	√	√	√	√	√
Growth factors	√	√	√	√	√	√	√

NCV: nerve conduction velocity; TCSS: Toronto Clinical Scoring System; Routine tests included the test of blood pressure, heart rate, BMI, blood and urine routine examination, hepatic and renal function, and coagulation function. Inflammatory cytokines included IL-6, TNF- α , IL-10, and sICAM-1. Growth factors included VEGF and NGF.

Supplement Table 2. Nerve Conduction studies before and after BM-MNCs therapy

Groups	Baseline	Post-transplantation	
		12 weeks	48 weeks
sNCV (m/s)			
All (n=60)	32.91 ± 2.20	35.44 ± 2.80	33.82 ± 2.49
<i>p value</i>	--	0.000	0.000
Responders (n=35)	32.87 ± 2.31	36.81 ± 2.50	34.26 ± 2.83
<i>p value</i>	--	0.000	0.000
Non-responders (n=19)	32.95 ± 2.08	33.40 ± 2.11	33.03 ± 1.45
<i>p value</i>	--	0.295	0.843
SNAP			
All (n=60)	4.34 ± 0.49	5.23 ± 0.60	4.78 ± 0.89
<i>p value</i>	--	0.000	0.003
Responders (n=35)	4.33 ± 0.48	5.41 ± 0.45	5.09 ± 0.87
<i>p value</i>	--	0.000	0.000
Non-responders (n=19)	4.31 ± 0.44	4.78 ± 0.64	4.20 ± 0.59
<i>p value</i>	--	0.029	0.523
mNCV (m/s)			
All (n=60)	33.63 ± 2.10	35.23 ± 3.02	34.19 ± 2.61
<i>p value</i>	--	0.000	0.005
Responders (n=35)	33.83 ± 2.20	36.07 ± 2.82	34.76 ± 2.64
<i>p value</i>	--	0.000	0.000
Non-responders (n=19)	33.26 ± 1.90	33.66 ± 2.78	33.16 ± 2.27
<i>p value</i>	--	0.346	0.778
CMAP			
All (n=60)	3.93 ± 0.50	5.42 ± 0.74	5.05 ± 0.88
<i>p value</i>	--	0.000	0.000
Responders (n=35)	3.99 ± 0.53	5.62 ± 0.76	5.38 ± 0.83
<i>p value</i>	--	0.000	0.000
Non-responders (n=19)	3.86 ± 0.51	4.91 ± 0.50	4.43 ± 0.60
<i>p value</i>	--	0.000	0.006

Data presented as mean ± standard deviation. P value: statistical difference between groups of baseline and each follow-up visit after transplantation; -: not applicable; CMAP: compound muscle action potential; mNCV: motor nerve conduction velocity; SNAP: sensory nerve action potential; sNCV: sensory nerve conduction velocity.

Supplement Table 3. TCSS before and after BM-MNCs therapy

Groups	Baseline	Post-transplantation			
		4 weeks	12 weeks	24 weeks	48 weeks
All (n=60)	10.13 ± 1.11	7.52 ± 1.19	6.95 ± 1.20	7.60 ± 0.95	8.13 ± 0.97
<i>p value</i>	--	0.000	0.000	0.000	0.000
Responders (n=35)	9.97 ± 1.25	7.40 ± 1.22	6.77 ± 1.06	7.43 ± 0.92	8.00 ± 0.97
<i>p value</i>	--	0.000	0.000	0.000	0.000
Non-responders (n=19)	10.16 ± 0.77	7.42 ± 1.12	7.26 ± 1.37	7.79 ± 0.92	8.37 ± 0.96
<i>p value</i>	--	0.000	0.000	0.000	0.000

Data presented as mean ± standard deviation. P value: statistical difference between groups of baseline and each follow-up visit after transplantation; -: not applicable; TCSS: Toronto Clinical Scoring System

Supplement Table 4. The change of neuropathic symptoms before and after BM-MNCs therapy

Neuropathic symptoms	Baseline n=60	Post-transplantation			
		4 weeks n=60	12 weeks n=60	24 weeks n=58	48 weeks n=54
Foot pain	60 (100.0%)	27 (45.0%)	28 (46.7%)	36 (62.1%)	40 (74.1%)
<i>p value</i>	--	0.000	0.000	0.000	0.000
Numbness	58 (96.7%)	41 (68.3%)	39 (65.0%)	39 (67.2%)	38 (70.4%)
<i>p value</i>	--	0.000	0.000	0.000	0.000
Tingling	56 (93.3%)	48 (80.0%)	46 (76.7%)	49 (84.4%)	48 (88.9%)
<i>p value</i>	--	0.058	0.019	0.150	0.514
Weakness	58 (96.7%)	20 (33.3%)	12 (20.0%)	19 (32.8%)	33 (61.1%)
<i>p value</i>	--	0.000	0.000	0.000	0.000
Ataxia	10 (16.7%)	8 (13.3%)	6 (10.0%)	6 (10.3%)	7 (13.0%)
<i>p value</i>	--	0.799	0.421	0.422	0.610

Data presented as n (%). P value: statistical difference between baseline and each follow-up visit after transplantation; -: not applicable.